BIOKERALTY Research was constituted in 2006 with the aim of gathering the R&D activities in new medicines of the pharmaceutical Praxis Group, established in Vitoria (Spain). The company is mainly devoted to the R&D activities in the field of APIs (Active Pharmaceutical Ingredients) obtained from biotechnology and biochemistry processes. One of its main strategic lines is focused on regenerative medicine for the treatment of chronic wounds. BIOKERALTY is highly active in R&D for the development of novel therapeutic alternatives for cancer, using nanotechnology and biological molecules like proteins and peptides. Moreover, is also working in controlled release systems through microparticles and other nanoparticles (Solid Lipid Nanoparticles, Magnetic Nanoparticles, Lipid Nanovesicles), which improve therapeutic action of APIS and allow protection of biological molecules and targeting, imaging and future theragnostic of different diseases including cancer.